Novo Nordisk (NVO.US) received approval from the European Union to inject the diabetes drug Kyinsu on a weekly basis.

Wisdom Financial App learned that Novo Nordisk's once-weekly injectable diabetes drug has been approved by the European Union, providing patients with another treatment option. The European Medicines Agency's drug review group has recommended approval of Kyinsu for the treatment of type 2 diabetes patients. This combination injection, known as IcoSema, consists of insulin and semaglutide (the active ingredient in Novo Nordisk's popular weight-loss drug Ozempic).